BRPI1015215A2 - porções de ligação alvo armadas com amatoxina para o tratamento de câncer - Google Patents
porções de ligação alvo armadas com amatoxina para o tratamento de câncerInfo
- Publication number
- BRPI1015215A2 BRPI1015215A2 BRPI1015215A BRPI1015215A BRPI1015215A2 BR PI1015215 A2 BRPI1015215 A2 BR PI1015215A2 BR PI1015215 A BRPI1015215 A BR PI1015215A BR PI1015215 A BRPI1015215 A BR PI1015215A BR PI1015215 A2 BRPI1015215 A2 BR PI1015215A2
- Authority
- BR
- Brazil
- Prior art keywords
- amatoxin
- cancer treatment
- target binding
- binding moieties
- armed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16769009P | 2009-04-08 | 2009-04-08 | |
| PCT/EP2010/002206 WO2010115630A1 (en) | 2009-04-08 | 2010-04-08 | Amatoxin-armed target-binding moieties for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1015215A2 true BRPI1015215A2 (pt) | 2016-06-28 |
Family
ID=42272251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1015215A BRPI1015215A2 (pt) | 2009-04-08 | 2010-04-08 | porções de ligação alvo armadas com amatoxina para o tratamento de câncer |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20120213805A1 (pt) |
| EP (1) | EP2416805B1 (pt) |
| JP (1) | JP2012523383A (pt) |
| KR (1) | KR20110140124A (pt) |
| CN (1) | CN102387815A (pt) |
| AU (1) | AU2010234335A1 (pt) |
| BR (1) | BRPI1015215A2 (pt) |
| CA (1) | CA2756246A1 (pt) |
| IL (1) | IL215108A0 (pt) |
| MX (1) | MX2011010469A (pt) |
| RU (1) | RU2011145038A (pt) |
| SG (1) | SG174328A1 (pt) |
| WO (1) | WO2010115630A1 (pt) |
| ZA (1) | ZA201106586B (pt) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2829283T (pt) | 2003-04-30 | 2017-09-08 | Univ Zuerich | Método para tratamento do cancro utilizando uma imunotoxina |
| ES2402254T3 (es) * | 2010-09-30 | 2013-04-30 | Heidelberg Pharma Ag | Conjugados de amatoxinas con ligadores mejorados |
| EP2497499A1 (en) | 2011-03-10 | 2012-09-12 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkages |
| CA2858806A1 (en) | 2011-12-23 | 2013-06-27 | Innate Pharma | Enzymatic conjugation of polypeptides |
| EP2684865A1 (en) | 2012-07-13 | 2014-01-15 | Heidelberg Pharma GmbH | Methods for synthesizing amatoxin building block and amatoxins |
| EP2872894B1 (en) | 2012-07-13 | 2019-04-17 | Innate Pharma | Screening of conjugated antibodies |
| EP2916872B1 (en) | 2012-11-09 | 2019-02-27 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
| EP2774624A1 (en) | 2013-03-04 | 2014-09-10 | Heidelberg Pharma GmbH | Amatoxin derivatives |
| EP2777714A1 (en) * | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
| US10611824B2 (en) | 2013-03-15 | 2020-04-07 | Innate Pharma | Solid phase TGase-mediated conjugation of antibodies |
| CA2909153A1 (en) * | 2013-04-12 | 2014-10-16 | Viventia Bio Inc. | Compositions and methods for detection and treatment of hepatocellular carcinoma |
| WO2014202773A1 (en) | 2013-06-20 | 2014-12-24 | Innate Pharma | Enzymatic conjugation of polypeptides |
| KR20160042871A (ko) | 2013-06-21 | 2016-04-20 | 이나뜨 파르마, 에스.아. | 폴리펩티드의 효소적 콘쥬게이션 |
| PL3052525T3 (pl) | 2013-10-02 | 2020-03-31 | Viventia Bio Inc. | Przeciwciała anty- EpCAM i sposoby wykorzystania |
| CN105377304B (zh) * | 2014-03-10 | 2018-05-15 | 海德堡医药有限责任公司 | 鹅膏毒肽衍生物 |
| EP3215519A1 (en) | 2014-11-06 | 2017-09-13 | Novartis AG | Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase |
| BR122020025870B1 (pt) | 2014-12-23 | 2024-01-09 | Nbe-Therapeutics Ag | Método para a produção de um conjugado de proteína de ligaçãofármaco |
| BR112017018861A2 (pt) * | 2015-03-04 | 2018-04-24 | Board Of Regents, The Unibersity Of Texas System | métodos para tratar câncer mantendo perda hemizigótica de tp53 |
| DK3268047T3 (da) | 2015-03-09 | 2024-01-02 | Heidelberg Pharma Res Gmbh | Amatoxin/antistof-konjugater |
| CA2979400A1 (en) | 2015-03-12 | 2016-09-15 | Viventia Bio Inc. | Dosing strategies for targeting epcam positive bladder cancer |
| WO2016145349A1 (en) | 2015-03-12 | 2016-09-15 | Viventia Bio Inc. | Methods of treatment for epcam positive bladder cancer |
| US10723766B2 (en) | 2015-11-27 | 2020-07-28 | Heidelberg Pharma Research Gmbh | Derivatives of gamma-amanitin |
| EP3222292A1 (en) | 2016-03-03 | 2017-09-27 | Heidelberg Pharma GmbH | Amanitin conjugates |
| US10464969B2 (en) | 2016-05-05 | 2019-11-05 | Novartis Ag | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase |
| US10111966B2 (en) | 2016-06-17 | 2018-10-30 | Magenta Therapeutics, Inc. | Methods for the depletion of CD117+ cells |
| CN109641051A (zh) | 2016-06-17 | 2019-04-16 | 美真达治疗公司 | 用于耗尽细胞的组合物和方法 |
| BR112019012937A2 (pt) * | 2016-12-23 | 2019-12-10 | Heidelberg Pharma Research Gmbh | novo conjugado de amanitina |
| SG11201906319XA (en) * | 2017-01-20 | 2019-08-27 | Magenta Therapeutics Inc | Compositions and methods for the depletion of cd137+ cells |
| CN110997676B (zh) | 2017-08-07 | 2022-12-20 | 海德堡医药研究有限责任公司 | 合成鹅膏蕈碱的新方法 |
| CA3066867A1 (en) | 2017-08-07 | 2019-02-14 | Heidelberg Pharma Research Gmbh | Novel method for synthesizing amanitins |
| AU2018317611B2 (en) | 2017-08-18 | 2022-03-10 | Systimmune, Inc. | Non-natural amatoxin-type antibody conjugate |
| AU2018337671B2 (en) | 2017-09-19 | 2021-03-04 | Paul Scherrer Institut | Transglutaminase conjugation method and linker |
| WO2019057964A1 (en) | 2017-09-22 | 2019-03-28 | Heidelberg Pharma Research Gmbh | AMANITINE CONJUGATES TARGETING PSMA |
| WO2019092148A1 (en) | 2017-11-10 | 2019-05-16 | Innate Pharma | Antibodies with functionalized glutamine residues |
| AU2018374283B2 (en) | 2017-11-29 | 2025-09-18 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD5+ cells |
| JP7598312B2 (ja) * | 2018-07-23 | 2024-12-11 | ハイデルベルク ファーマ リサーチ ゲーエムベーハー | 同種異系の細胞療法における抗－ｃｄ１３７抗体薬物コンジュゲート（ａｄｃ）の使用 |
| EP3826625A4 (en) * | 2018-07-23 | 2022-08-24 | Magenta Therapeutics, Inc. | USE OF ANTI-CD5 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENE CELL THERAPY |
| TWI897855B (zh) * | 2018-10-26 | 2025-09-21 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| CN109796537A (zh) * | 2019-02-28 | 2019-05-24 | 中国农业大学 | 一种β-鹅膏毒肽人工抗原及其制备方法与应用 |
| KR102996570B1 (ko) * | 2019-05-23 | 2026-07-27 | 하이델베르크 파마 리서치 게엠베하 | 절단 가능한 링커를 가진 항체 약물 접합체 |
| EP4213886A1 (en) | 2020-09-18 | 2023-07-26 | Araris Biotech AG | Transglutaminase conjugation method with amino acid-based linkers |
| JP7789396B2 (ja) | 2020-10-25 | 2025-12-22 | アラリス バイオテック アーゲー | 抗体－リンカーコンジュゲートを生成するための手段および方法 |
| EP4422695A1 (en) | 2021-10-25 | 2024-09-04 | Araris Biotech AG | Methods for producing antibody-linker conjugates |
| KR20240150807A (ko) | 2022-02-22 | 2024-10-16 | 아라리스 바이오테크 아게 | 2개 이상의 페이로드를 포함하는 펩티드 링커 |
| WO2025082990A1 (en) | 2023-10-15 | 2025-04-24 | Araris Biotech Ag | Antibody-drug conjugates using two different types of topoisomerase i inhibitors |
| WO2026013234A1 (en) | 2024-07-10 | 2026-01-15 | Araris Biotech Ag | Triple-payload antibody-drug conjugates (adcs) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| EP1661584A1 (en) * | 2004-11-26 | 2006-05-31 | Heinz Dr. Faulstich | Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy |
| ATE521366T1 (de) * | 2006-05-27 | 2011-09-15 | Faulstich Heinz Dr | Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen |
| EP3192529B1 (en) * | 2009-04-08 | 2020-03-25 | Faulstich, Heinz, Dr. | Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy |
-
2010
- 2010-04-08 MX MX2011010469A patent/MX2011010469A/es not_active Application Discontinuation
- 2010-04-08 RU RU2011145038/15A patent/RU2011145038A/ru not_active Application Discontinuation
- 2010-04-08 JP JP2012503923A patent/JP2012523383A/ja active Pending
- 2010-04-08 AU AU2010234335A patent/AU2010234335A1/en not_active Abandoned
- 2010-04-08 SG SG2011065356A patent/SG174328A1/en unknown
- 2010-04-08 US US13/260,328 patent/US20120213805A1/en not_active Abandoned
- 2010-04-08 CN CN2010800166488A patent/CN102387815A/zh active Pending
- 2010-04-08 BR BRPI1015215A patent/BRPI1015215A2/pt not_active IP Right Cessation
- 2010-04-08 WO PCT/EP2010/002206 patent/WO2010115630A1/en not_active Ceased
- 2010-04-08 EP EP10718864.1A patent/EP2416805B1/en active Active
- 2010-04-08 CA CA2756246A patent/CA2756246A1/en not_active Abandoned
- 2010-04-08 KR KR1020117023028A patent/KR20110140124A/ko not_active Withdrawn
-
2011
- 2011-09-08 ZA ZA2011/06586A patent/ZA201106586B/en unknown
- 2011-09-12 IL IL215108A patent/IL215108A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20120213805A1 (en) | 2012-08-23 |
| RU2011145038A (ru) | 2013-05-20 |
| IL215108A0 (en) | 2011-12-29 |
| SG174328A1 (en) | 2011-10-28 |
| EP2416805B1 (en) | 2013-07-24 |
| MX2011010469A (es) | 2012-03-14 |
| WO2010115630A1 (en) | 2010-10-14 |
| CA2756246A1 (en) | 2010-10-14 |
| ZA201106586B (en) | 2012-11-28 |
| CN102387815A (zh) | 2012-03-21 |
| AU2010234335A1 (en) | 2011-10-13 |
| EP2416805A1 (en) | 2012-02-15 |
| JP2012523383A (ja) | 2012-10-04 |
| KR20110140124A (ko) | 2011-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1013618A2 (pt) | pirimidinas substituídas para o tratamento de câncer | |
| BR112012005594A2 (pt) | tratamento de câncer | |
| BRPI1010874A2 (pt) | composição para o tratamento de câncer de próstata | |
| EP2381953A4 (en) | TARGETED ANTIMICROBIAL ELEMENTS | |
| PT2456889E (pt) | Marcadores para o cancro do endométrio | |
| DE602008005894D1 (de) | Kondensierte imidazole zur krebsbehandlung | |
| PT2515855E (pt) | Terapêutica de combinação para dpoc | |
| HUE045548T2 (hu) | Rák kezelésére hasznos gyógyszer | |
| BRPI1009919A2 (pt) | combinações de pentamidina para tratamento de câncer. | |
| BRPI1006438A2 (pt) | terapia adjuvante de cancer | |
| BRPI1007972A2 (pt) | composições de combinação e métodos para o tratamento de câncer | |
| BRPI0922884A2 (pt) | compostos para tratamento de câncer | |
| ZA201106586B (en) | Amatoxin-armed target-binding moieties for the treatment of cancer | |
| PT2340042E (pt) | Métodos e composições para o tratamento de cancro | |
| EP2606130A4 (en) | CAMKK-BETA AS A TARGET TO TREAT CANCER | |
| BRPI1008566A2 (pt) | métodos e composições para o diagnóstico e tratamento de câncer | |
| BRPI1007995A2 (pt) | orto-aminoamidas para o tratamento de cãncer. | |
| BR112012000502A2 (pt) | terapia de combinação para o tratamento de diabetes | |
| BR112012002797A2 (pt) | tratamento de câncer de próstata | |
| BRPI0909016A2 (pt) | anticorpos úteis para o tratamento do câncer | |
| BRPI0812040A2 (pt) | Indicações para terapia de anti-il-i-beta | |
| ZA201203449B (en) | Sulfoxide derivatives for treating tumors | |
| BRPI0818170A2 (pt) | 5-cianotienopiridinas para o tratamento de tumores. | |
| BRPI0922367A2 (pt) | enzastaurin para o tratamento de câncer | |
| HUE038563T2 (hu) | Rák kezelési eljárás |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B15K | Others concerning applications: alteration of classification |
Ipc: C07K 16/30 (2006.01), A61K 47/68 (2017.0 |